Scientific Approach

Developing differentiated mAbs for immune-mediated diseases

Climb is leveraging clinically validated B cell targets and proven monoclonal antibody (mAb) approaches to develop differentiated disease-modifying therapies for immune-mediated diseases. Our programs aim to deliver strong clinical profiles and unlock treatments that could have a meaningful impact to patients.

We maximize the probability of success by focusing on:

• Validated targets: Clinically proven B cell targets with the potential to disrupt pathogenic cycles effectively and durably
• Proven therapeutic modality: Monoclonal antibody candidates designed for high specificity, potency, and patient convenience
• Optimal indication selection: Indications with high unmet need, clear endpoints, and established regulatory pathways